Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation

Reproductive BioMedicine Online

Volumn 7, Issue 3, 2003, Pages 319-326

  Pang, Samuel C ^a,h   Kaplan, B ^b   Karande, V ^c   Westphal, L M ^d   Scott, R ^e   Givens, C ^f   Sacks, P ^g  

^a Reproductive Science Center of Boston   (United States)

^b Fertility Centers of Illinois   (United States)

^c Department of Gynecology/Obstetrics ^*

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e REPRODUCTIVE MEDICINE ASSOCIATES OF NEW JERSEY   (United States)

^f Pacific Fertility Center   (United States)

^g Columbia Fertility Associates   (United States)

^h Reproductive Science Center of New England   (United States)

Author keywords

Infertility; Ovarian stimulation; Pen injector; Recombinant FSH

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLISTIM AQ CARTRIDGE; GANIRELIX; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG SOLUTION; DRUG TOLERABILITY; FEMALE; FEMALE INFERTILITY; HORMONAL REGULATION; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE DRUG DOSE; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PRURITUS; QUESTIONNAIRE; RASH; SELF INJECTION; SKIN BRUISING; SKIN EDEMA;

EID: 0141994952     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)61871-8     Document Type: Article

References (16)

1. Bohannon NJ 1999 Insulin delivery using pen devices - simple to use tools may help young and old alike. Postgraduate Medicine 106, 57-68.
2. Craenmehr E, Bontje PM, Hoomans E et al. 2001 Follitropin beta administered by pen device has superior local tolerance compared with follitropin-α administered by conventional syringe. Reproductive BioMedicine Online 3, 185-189.
3. Dunbar JM, Madden PM, Gleeson DT et al. 1994 Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 17, 874-878.
4. Fluker M, Grifo J, Leader A et al. 2001 Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 75, 38-45.
5. Kadiri A, Chraibi A, Marouan F et al. 1998 Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM subjects with secondary failure to oral hypoglycaemic agents. Diabetes Research and Clinical Practice 41, 15-23.
6. Kolibianakis EM, Albano C, Kahn J et al. 2003 Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertility and Sterility 79, 873-880.
7. Mannaerts BMJL, Rombout F, Out HJ et al. 1996 Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Human Reproduction Update 2, 153-161.
8. Out HJ, Mannaerts BMJL, Driessen SGAJ et al. 1995 A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puergon versus Metrodin) in in-vitro fertilization. Human Reproduction 10, 2534-2540.
9. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT 1997 Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertility and Sterility 68, 138-142.
10. Platteau P, Laurent E, Albano C et al. 2003 An open, randomized, single-centre Study to compare the efficacy and convenience of Follitropin beta administered by a pen device with follitropin alfa administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI. Human Reproduction 18, 1-5.
11. Schmidt L, Münster K, Helm P 1995 Infertility and the seeking of infertility treatment in a representative population. British Journal of Obstetrics and Gynaecology 102, 978-984.
12. Society for Assisted Reproductive Technology 1999 1999 National Survey (compiled by the Centers for Disease Control and Prevention, Birmingham, AL, USA).
13. Stephen EH, Chandra A 2000 Use of infertility services in the United States: 1995. Family Planning Perspectives 32, 132-137.
14. Sucic M, Galic E, Cabrijan T et al. 2002 Patient acceptance and reliability of new Humulin®/Humalog® 3.0 ml prefilled insulin pen in ten Croatian diabetes centres. Medical Science Monitor 8, P121-P126.
15. The North American Follistim® Study Group 2003 An aqueous formulation of recombinant human FSH is more efficient than a freeze-dried cake formulation in clomiphene-resistant women with anovulation. Reproductive BioMedicine Online, in press.
16. Voortman G, van de Post J, Schoemaker RC, van Gerven MA 1999 Bioequivalence of subcutaneous injections of recombinant human follicle stimulating hormone (Puregon®) by Pen-injector and syringe. Human Reproduction 14, 1698-1702.